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Thyroid hormone (T3) plays a crucial role in pro-
cesses such as cell proliferation and differentia-
tion, whereas its implication on cellular apoptosis
has not been well documented. Here we examined
the effect of T3 on the apoptosis of GH4C1 pituitary
cells and the mechanisms underlying this effect.
We show that T3 produced a significant increase in
apoptosis in serum-depleted conditions. This ef-
fect was accompanied by a decrease in nuclear
factor-B (NF-B)-dependent transcription, IB
phosphorylation, translocation of p65/NF-B to the
nucleus, phosphorylation, and transactivation.
Moreover, these effects were correlated with a T3-
induced decrease in the expression of antiapop-
totic gene products, such as members of the in-
hibitor of apoptosis protein and Bcl-2 families. On
the other hand, ERK but not c-Jun N-terminal ki-
nase or MAPK p38, was activated upon exposure
to T3, and inhibition of ERK alone abrogated T3-
mediated apoptosis. In addition, T3 increased the
expression of the MAPK phosphatase, dual spec-
ificity phosphatase 1 (DUSP1), in an ERK-depen-
dent manner. Interestingly, the suppression of
DUSP1 expression abrogated T3-induced inhibi-
tion of NF-B-dependent transcription and p65/
NF-B translocation to the nucleus, as well as
T3-mediated apoptosis. Overall, our results indi-
cate that T3 induces apoptosis in rat pituitary
tumor cells by down-regulating NF-B activity
through a mechanism dependent on the ERK/
DUSP1 pathway. (Molecular Endocrinology 22:
2466–2480, 2008)
THETHYROID HORMONE T3 influences a variety ofphysiological processes in mammals, including
cell growth and metabolism (1). Most, if not all, of
these actions are mediated by nuclear T3 receptors,
which are widely expressed in mammalian tissues.
Pituitary somatolactotrope cells are a well-established
target of T3 and require trophic support for survival in
culture (2). GH4C1 cells, which are derived from a rat
pituitary tumor, have been widely used as an in vitro
model to understand the mechanisms of T3 action (3).
Nevertheless, there is still certain controversy regard-
ing the effect of T3 and its receptors on cell prolifera-
tion. In fact, the cell type, as well as the developmental
or pathophysiological state, appears to determine
whether T3 activates (4–6) or blocks (7–10) the prolif-
eration of many cultured cells through mechanisms,
involving either growth factors, MAPK pathways, cy-
clins, or the tumor suppressor p53. In particular, T3
has been shown to modulate the proliferation of dif-
ferent rat pituitary cell lines and it is known to promote
the division of GH4C1 cells by stimulating the secre-
tion of an autocrine growth factor (11). Indeed, T3
stimulates growth of GC cells by shortening the G1
phase of the cell cycle (12). Moreover, it has been
shown that T3-dependent cell growth of GH1 cells
requires a serum-derived mediator for T3 responsive-
ness (13). In contrast, exposing the GH3 pituitary cell
line to T3 was recently shown to increase the expres-
sion of mitochondrial proapoptotic molecules Bax and
Bak, while decreasing that of the antiapoptotic Bcl-2,
potentially initiating an apoptotic response (14).
The inducible nuclear factor-B (NF-B) is an im-
portant transcription factor involved in the regulation
of immune, inflammatory, apoptotic, and carcinogenic
processes in response to a wide variety of stimuli (15,
16). Under resting conditions, NF-B exists in the cy-
toplasm as a heterotrimer of p50, p65, and IB. The
phosphorylation, ubiquitination, and degradation of
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IB lead to the translocation of NF-B complexes to
the nucleus, where they bind to specific DNA response
elements (17). In addition, several studies have shown
that posttranslational modification of NF-B proteins,
including phosphorylation, can influence its transcrip-
tional activity (18). NF-B regulates the expression of a
large number of genes the products of which are
involved in apoptosis, including several members of
the inhibitor of apoptosis proteins (IAP) and the
Bcl-2 families (19).
The MAPK family comprises related serine/threo-
nine protein kinases that direct cellular responses to
proliferative cues or stressful stimuli, integrating dif-
ferent signals (20). Conventional members of the
MAPK family include the ERKs, the c-Jun N-terminal
kinases (JNKs), and MAPK p38. These MAPKs regu-
late diverse cell activities such as gene expression,
proliferation, differentiation, and apoptosis (21–23). In
general, it is accepted that JNK and MAPK p38 mainly
promote apoptosis, whereas ERK activation is typi-
cally associated with cell survival, proliferation, and
differentiation, as reflected by its activation by mito-
gens and some cell survival factors (23). However,
activation of ERK by different stimuli has recently been
found to contribute to cell death in certain cell types. In
this regard, a persistent activation of ERK has been
shown to induce cell death in primary neuron cultures
(24), rat hepatocytes (25), and TtT-97 mouse thyro-
trope tumor cells (26, 27). Interestingly, a correlation
between ERK activation and cell death has also been
shown in the pituitary, and sustained ERK activation
in GH3 pituitary cells increases cell death (28). Sim-
ilarly, epidermal growth factor triggers programmed
cell death in pituitary GH4C1 cells by a mechanism
involving ERK activation and the down-regulation of
Bcl-2 (29).
MAPK phosphatases dephosphorylate MAPK at
Thr/Tyr residues critical for activation, thereby contrib-
uting to the down-regulation of MAPK activity. Dual
specificity phosphatase 1 (DUSP1), also known as
MAPK phosphatase 1, is the founder member of this
family, and it is induced by a variety of stimuli including
growth factors, nuclear receptors, and stress stimuli
(30). The expression of DUSP1 can be regulated
through multiple pathways involving both transcrip-
tional and posttranscriptional mechanisms, and inhi-
bition of ERK substantially impairs the induction of
DUSP1 by different stimuli (31, 32). DUSP1 has re-
cently been identified in several cells as a critical reg-
ulator of many activities, including control of the ho-
meostatic balance (33), immune challenge (34),
inflammation (35), and proliferation or apoptosis (36,
37). In particular, the role of DUSP1 in apoptosis is
controversial although it has been shown to be funda-
mental to prevent the cell death induced by chemo-
therapy agents in diverse tumor cells (37–39). More-
over, oxidative stress-mediated cell death is enhanced
in DUSP1/ mouse embryonic fibroblasts (40). By
contrast, a proapoptotic role for DUSP1 has been
described in other systems, and DUSP1 can mediate
the ERK-dependent cell death induced by diverse
stimuli in primary neuron cultures (41, 42) and in
NIH3T3 cells (43). Interestingly, a link between DUSP1
induction and the antiproliferative effects of glucocor-
ticoids in osteoblasts has also been demonstrated
recently (44).
In this study, for the first time we demonstrate cross
talk between T3 signaling and both the NF-B and the
ERK/DUSP1 pathways in GH4C1 pituitary cells. We
show that T3 induces apoptosis in serum-starved
GH4C1 cells, which is an established model for ana-
lyzing apoptotic pathways (45). This effect is con-
trolled by a complex mechanism that involves the
inhibition of NF-B activity by induction of DUSP1,
which in turn is dependent on ERK activation. These
results could contribute to better understanding the
molecular mechanism of action of T3 in different phys-
iopathological situations in pituitary cells.
RESULTS
Thyroid Hormone Induces Cell Death in the
Serum-Starved Cells
T3 plays a crucial role in cell proliferation and differ-
entiation in different cell contexts. To evaluate the
effects of T3 on the apoptosis of GH4C1 cells, we first
analyzed the sub-G1 hypodiploid cell population by
flow cytometry after propidium iodide (PI) staining.
Cells were cultured for 48 h in growth medium sup-
plemented with 10% charcoal-stripped-fetal bovine
serum (FBS) (control) or 0.1% charcoal-stripped-FBS
[serum-deprived (SD)], in the absence or presence of
T3 (Fig. 1A). As expected, T3 did not induce apoptosis
when added in the presence of 10% serum. However,
exposure to T3, in combination with the proapoptotic
stimulus serum deprivation, induced apoptosis that
affected about 25% of the cell population after 48 h.
Apoptosis was induced by 10% by exposure to T3 for
24 h when added in serum-depleted conditions,
whereas T3 appeared to be cytotoxic at 72 h (data not
shown). For this reason the 48-h incubation time was
chosen in subsequent experiments for analyzing the
apoptotic mechanism employed by T3.
Apart from PI staining, annexin V can be used to
mark the redistribution of phosphatidylserine to the
outer leaflet of the plasma membrane, a hallmark of
programmed cell death. Cells were treated in the same
conditions as in Fig. 1A, stained with both annexin V
and PI, and analyzed by flow cytometry (Fig. 1B). The
data show that in high serum conditions 93.49% of
cells were viable (annexin V and PI double negative),
and that the percentage of early apoptotic cells (an-
nexin V single positive) or late apoptotic cells (annexin
V and PI double positive) was low (3.89% and 2.89%,
respectively). The PI-positive cells were labeled as
necrotic and accounted for 1.80% of the cell popula-
tion. Treatment of the cells with T3 did not significantly
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modify these percentages. However, when cells were
incubated in the presence of 0.1% serum (SD), viability
decreased to 73.53%, and the percentages of cell
population that displayed early or late apoptosis were
increased up to 5.25% and 7.48%, respectively. The
treatment with T3 in low serum further reduced the
viable cells to about 67.84%, but augmented the per-
centages of the cells in both the early and the late
stage of apoptosis up to 9.21% and 12.65%, respec-
tively (SD T3). Thus, dual staining with annexin V and
PI allowed clear discrimination between unaffected
cells, early apoptotic cells, and late apoptotic cells.
Fig. 1. Thyroid Hormone Induces Cell Death
A, GH4C1 cells were incubated for 48 h in medium supplemented with 10% (control) or 0.1% (SD) charcoal-stripped-FBS in
the presence or absence of T3 (5 nM). Apoptosis was determined in PI-stained cells and analyzed by flow cytometry. The values
represent the mean  SD of three independent experiments performed in duplicate. B, GH4C1 cells were incubated as in panel
A or panel D, and apoptosis was examined by the Annexin V/PI dual-staining assay, as detected by flow cytometry. A
representative experiment is shown. C, Cells were incubated as in panel A, and Western blotting was performed to determine the
expression of PARP, ensuring equal protein loading with -actin. A representative experiment is shown. D and E, Cells were
incubated for 48 h in medium supplemented with 10% charcoal-stripped-FBS in the presence or absence of T3 (5 nM), and
staurosporine (STS, 500 nM) was added for the last 24 h. Apoptosis levels shown in panels D and E were measured as in panels
A and C, respectively. F, GH1 or GH3B6 cells were incubated for 48 h or 72 h, respectively, in medium supplemented with 10%
(control) or 0.1% (SD) charcoal-stripped-HS in the presence or absence of 5 nM T3 (GH1 cells) or 100 nM (GH1 and GH3B6 cells).
Apoptosis levels were measured as in panel A. FITC, Fluorescein isothiocyanate.
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To further verify that T3 did indeed mediate apopto-
sis, we examined the effects of T3 treatment on the
caspase-induced cleavage of polyadenosine ribose
polymerase (PARP, Fig. 1C). The results obtained in-
dicate that although low levels of PARP cleavage were
detected in GH4C1 cells incubated in low serum,
cleavage increased in the presence of T3. In contrast,
PARP was not cleaved in cells incubated with T3 plus
10% serum. These results indicate that the enhanced
cytotoxicity induced by T3 in low serum was indeed
due to apoptosis. The above results, together with
additional data showing that T3 reduces the tetra-
methyl rhodamine methyl ester fluorescence and in-
duces mitochondrial depolarization in GH4C1 cells
(data not shown) confirmed the proapoptotic effect of
T3 when cells were SD.
To evaluate whether the effects of T3 on apoptosis
were dependent on the apoptotic trigger employed,
the cells were incubated under high serum conditions
in the presence or absence of staurosporine, a known
proapoptotic stimulus in GH4C1 cells (29), and apo-
ptosis was analyzed by flow cytometry after PI staining
(Fig. 1D). The results showed that about 20% of cells
undergo apoptosis upon incubation with staurospor-
ine, and that T3 increased apoptosis up to about 40%
(Fig. 1D). Apoptosis was also assessed by dual An-
nexin V and PI staining (Fig. 1B), and the results
showed that staurosporine caused both early and late
apoptosis in about 4.64% and 5.86% cell population,
respectively, vs. 3.89% and 2.89%, respectively, in
control cells. Incubation of the cells in the presence of
staurosporine plus T3 did raise the percentage of both
early and late apoptotic cells up to 6.64% and
15.21%, respectively (Fig. 1B). These results were
confirmed by the measurement of PARP cleavage,
which was detected after incubation with staurospor-
ine, and was enhanced by treatment of the cells with
staurosporine in combination with T3 (Fig. 1E).
To rule out cell type-specific effects of T3 on pitu-
itary cell apoptosis, we examined the effects of T3 on
apoptosis of the other rat pituitary cell lines. To that
purpose, GH1 or GH3B6 cells were incubated in the
same conditions as in Fig. 1A for 48 and 72 h (GH1
cells) or 72 h (GH3B6 cells), and apoptosis was mea-
sured by flow cytometry after PI staining (Fig. 1F). As
expected, T3 did not induce apoptosis when added in
the presence of 10% serum. However, exposure to T3
when cells were SD significantly induced apoptosis in
GH1 or GH3B6 cells. These results show that different
pituitary cell lines are susceptible to the proapoptotic
effect of T3 in low serum condition, revealing a po-
tential physiological relevance of T3 on pituitary
apoptosis.
NF-B Activity Is Inhibited by Thyroid Hormone in
Cells Grown in Low Serum
Because NF-B is a transcription factor known to be
involved in antiapoptotic processes, we determined
whether T3 might induce apoptosis by suppressing
NF-B activity. NF-B-dependent transcription was
measured in GH4C1 cells transfected with a luciferase
reporter (3x NF-B-Luc) after exposure for 48 h to T3
(Fig. 2A). T3 did not affect NF-B activity in cells grown
in 10% serum; however, in SD cells there was a 1.5-
fold increase in NF-B-dependent transcription, al-
though this activity was reduced by 60% by exposure
to T3 (Fig. 2A). By contrast, the thymidine kinase (TK)-
Luc control reporter showed a very low activity, which
was not modified in the presence of T3 (data not
shown). As mentioned previously, NF-B is regulated,
in part, by a cellular process that involves phosphor-
ylation and degradation of its inhibitory subunit IB,
permitting active NF-B complexes to translocate to
the nucleus and activate transcription. Thus, we mea-
sured the kinetics of IB degradation upon exposure
to T3 for 48 h and found that T3 did not significantly
modify the total IB levels in cytoplasmic extracts
from cells incubated under all conditions (Fig. 2B). We
next analyzed the effect of T3 on IB phosphorylation
and found that phosphorylated IB levels increased
after serum depletion, whereas T3 abrogated this ef-
fect (Fig. 2B). We then examined the effect of T3 on
p65/NF-B levels in cytosolic extracts, which re-
mained quite high and unchanged under all condi-
tions. In contrast, nuclear p65/NF-B levels increased
after serum depletion, although they were almost
completely suppressed after 48 h exposure to T3 (Fig.
2B). Because NF-B activity is enhanced by p65/
NF-B phosphorylation, we tested whether exposure
to T3 affected the phosphorylation of p65. A strong
reduction in p65/NF-B phosphorylation at Ser276
(pp65) was observed in cells cultured in low serum and
exposed to T3, whereas there was little phosphory-
lated nuclear p65/NF-B in cells grown in high serum
both in the presence or absence of T3 (Fig. 2B). The
levels of phosphorylated p65/NF-B were almost un-
detectable in cytosolic extracts from the same cells
and remained unchanged in any condition (Fig. 2B).
The levels of tubulin and histone H3 were used as
controls to validate the integrity of the cytoplasmic and
nuclear extracts, respectively (Fig. 2B).
Because we detected differences in the levels of
nuclear p65/NF-B after exposure to T3, we deter-
mined the NF-B binding activity in nuclear extracts
from cells that were incubated with T3 for 48 h. No
specific NF-B-DNA binding complexes were ob-
served when cells were incubated in the presence of
10% serum, whereas complex formation was induced
in low serum. Moreover, there was a decrease in the
NF-B-DNA binding complexes when these cells were
exposed to T3 (Fig. 2C).
NF-B may be activated by stimulation of the trans-
activation domain in the p65/NF-B subunit. There-
fore, we studied whether the differences observed
after T3 treatment were also dependent on the tran-
scriptional activation of p65/NF-B. We used a plas-
mid encoding the Gal4-p65 fusion protein to address
this question, where the sequences encoding the DNA
binding domain of Gal4 have been fused with se-
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quences encoding p65/NF-B. Its cotransfection with
a Gal4-Luc reporter plasmid allowed us to determine
whether cellular signals triggered by T3 regulate gene
expression by specifically targeting the p65/NF-B
protein. Like NF-B-dependent transcription, low se-
rum increased the basal activity of Gal4-p65 about
1.5-fold (Fig. 2D), and incubation of the cells with T3
decreased it by about 50%. By contrast, the Gal4
Fig. 2. NF-B Activity Is Inhibited by Thyroid Hormone
A, GH4C1 cells were transiently transfected with a NF-B-driven luciferase reporter plasmid (3 NF-B-TK-Luc) and pRL-
TK-Renilla and then treated with T3 (5 nM) for 48 h in the presence of 10% (control) or 0.1% (SD) charcoal-stripped-FBS. Cell
extracts were prepared and assayed for luciferase and Renilla activities. The luciferase levels were normalized to those of Renilla
and expressed as the induction over the controls. The data shown represent the mean  SD of three independent experiments
performed in duplicate. B, Cells were incubated with T3 (5 nM) in the presence of 10% (control) or 0.1% (SD) charcoal-stripped-
FBS for 48 h. The cytosolic extracts (CE) and the nuclear extracts (NE) were analyzed by Western blotting using antibodies against
IB, the phosphorylated form of IB (pIB), p65, and the phosphorylated form of p65 (pp65). Equal protein loading was
evaluated by -actin. The levels of tubulin and histone H3 were used as controls to validate the integrity of the cytoplasmic and
nuclear extracts, respectively. The blots shown are from one of three representative experiments. C, Cells were treated as in panel
B, and nuclear extracts were prepared and tested for NF-B binding activity by EMSA. TNF (10 ng/ml) was used as a positive
control. The asterisk indicates a nonspecific band. A representative experiment of three replicates is shown. D, Cells were
transiently transfected with the pGal4-Luc reporter and the pRL-TK-Renilla, together with either Gal4–p65 or the mutant
Gal4–p65(S276). Cells were then treated with T3 (5 nM) for 48 h in the presence of 10% (control) or 0.1% (SD) charcoal-stripped-
FBS. Luciferase levels in the cell extracts were assayed, normalized with Renilla, and expressed as the induction over controls.
The data shown represent the mean  SD of three independent experiments performed in duplicate.
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control reporter showed very low activity that was not
modified in the presence of T3 (data not shown). These
results indicate that T3 inhibits NF-B transcriptional
activity by reducing the potential p65/NF-B transac-
tivation. Because T3 affects p65/NF-B phosphoryla-
tion at Ser276 (Fig. 2B), we tested the effect of T3 on
the transactivation potential of a Gal4-p65 mutant
construct in which the Ser276 was replaced by cys-
teine [Gal4-p65(S276C)]. As expected, the basal ac-
tivity of this mutant was very low (Fig. 2D), and T3
further decreased the activity of this mutant by 39%,
albeit to a lesser extent than the Gal4-p65 activity,
which was reduced in T3-treated cells by 55.4%.
Hence, p65/NF-B phosphorylation at the Ser276
contributes to, but is not necessary for, the regulation
of p65/NF-B transactivation by T3.
Thyroid Hormone Alters the Levels of
NF-B-Dependent Antiapoptotic Genes
The results above suggest that T3 induces cell apo-
ptosis in low serum by a mechanism involving NF-B
inhibition. NF-B up-regulates the expression of sev-
eral genes involved in cell survival, including IAP and
members of the Bcl-2 family. To test whether T3 af-
fected the expression of these NF-B-responsive
genes, GH4C1 cells were incubated for 48 h in the
presence or absence of T3, and the expression of IAP
and Bcl-2 family members was determined by quan-
titative RT-PCR (QRT-PCR). Incubation of cells in low
serum induced the expression of the antiapoptotic
genes, rat inhibitor of apoptosis protein 1 (r-IAP1) and
3 (r-IAP3) (Fig. 3, A and B), and Bcl-xL (Fig. 3C), and
exposure to T3 provoked a marked decrease in the
expression of these genes. However, T3 did not greatly
modify the expression of r-IAP3 or Bcl-xL when added
to cells in 10% serum, although a mild reduction in
r-IAP1 expression was observed albeit less than in low
serum (Fig. 3A). The effects of T3 were not general,
because other members of these families, including sur-
vivin and r-IAP2, were neither expressed under basal
conditions nor affected by T3 treatment (data not shown).
These perturbations in the expression of the antiapop-
totic genesmight contribute to the potentiation of the cell
death caused by T3 in low serum.
The Apoptosis Induced By Thyroid Hormone Is
Specifically Mediated by ERK
JNK and MAPK p38 have been well characterized as
proapoptotic kinases that transduce cell death signal-
ing in many cell types (23). To further analyze the
mechanisms by which T3 induced apoptosis, we first
examined the effects of T3 on the activity of these
kinases by measuring their phosphorylation (Fig. 4A).
JNK phosphorylation was dramatically augmented by
serum depletion, although this modification was not
altered by T3 (Fig. 4A, upper panel). MAPK p38 phos-
phorylation was not detected in GH4C1 cells at either
concentration of serum or by the presence or absence
of T3 (Fig. 4A, middle panel). ERK is the other member
of the MAPK family involved in apoptosis in different
cell types. To analyze whether ERK was involved in T3-
mediated apoptosis, we examined the effects of T3 on
ERK activity (Fig. 4A, lower panel). Like JNK, incubation
of the cells in serum-depleted conditions stimulated
ERK, and T3 caused a further increase in this activation.
A discrete increase in ERK phosphorylation was also
observed in the presence of T3 and 10% serum.
To analyze the possible role of these proteins on T3-
induced apoptosis in GH4C1 cells, we next pretreated
the cells for 30 min with specific inhibitors of MAPK
pathways, followed by incubation with T3 for 48 h. Ex-
posing cells to the inhibitor of MAPK p38 (SB203580) or
JNK (SP600125) did not significantly alter T3-induced
apoptosis, whereas the phenomenon was completely
abrogated by incubation of the cells in the presence of
the MAPK/ERK kinase (MEK) inhibitor U0126 (Fig. 4B).
These results indicate that T3-induced apoptosis in
Fig. 3. Thyroid Hormone Alters the Levels of NF-B-Depen-
dent Antiapoptotic Genes
GH4C1 cells were maintained in the presence or absence
of 5 nM T3 in 10% (control) or 0.1% (SD) charcoal-stripped-
FBS for 48 h. Total RNA was prepared, and QRT-PCR was
carried out using primers against r-IAP1 (A), r-IAP3 (B), Bcl-xL
(C), and GAPDH. The mRNA levels were normalized by
GAPDH, and the results were expressed as the changes in
mRNA expression. The data shown represent the mean  SD
of three independent experiments.
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low serum is specifically mediated by the MEK/ERK
pathway.
Thyroid Hormone Induces DUSP1 at a
Posttranslational Level
To further examine the mechanism by which T3 in-
duces ERK-dependent apoptosis in GH4C1 cells, we
measured the levels of DUSP1, a dual specificity
phosphatase that dephosphorylates and deactivates
members of the MAPK family, and that has been
shown to be involved in apoptosis in many cell types.
Cells were first incubated for 48 h with T3 in normal or
low serum, and the levels of DUSP1 were then mea-
sured in total cell extracts by Western blotting. In the
presence of 10% serum, DUSP1 levels were almost
undetectable, and they were not significantly affected
by T3 (Fig. 5A). In contrast, serum depletion produced
a slight increase in DUSP1 expression by cells that
was further exacerbated by exposure to T3. Because
the induction of DUSP1 is dependent on MAPK path-
ways, we analyzed DUSP1 expression after exposure
to T3 in combination with specific MAPK inhibitors.
Strikingly, incubation of the cells in the presence of the
MEK inhibitor U0126 completely abolished the T3-
mediated induction of DUSP1 (Fig. 5B). By contrast,
the specific inhibitors of JNK or MAPK p38 did not
alter the levels of this phosphatase (data not shown).
This result indicates that T3 induces DUSP1 levels by
a mechanism dependent on the MEK/ERK pathway.
It has been previously established that activation of
ERK is sufficient to induce DUSP1 protein by a mech-
anism that implies an increase in its half-life (46). Be-
cause we have shown that T3 induces DUSP1 protein
in an ERK-dependent manner, we then investigated
whether T3 affected DUSP1 protein stability. First,
mRNA from T3-treated or control cells was subjected
to Northern blotting using a probe against DUSP1. As
shown in Fig. 5C, DUSP1 mRNA was expressed at
similar levels in control and T3-treated cells, confirm-
ing that T3 does not regulate DUSP1 expression at a
transcriptional level. We next examined the stability of
DUSP1 protein in GH4C1 cells. To that purpose, cyclo-
heximide was added to the cells after 48 h of T3 treat-
ment, and DUSP1 protein levels were measured by
Western blotting at different time points (Fig. 5D). As
expected, DUSP1 levels decayed very rapidly in control
cells, showing a half-life of 12  2.4 min. However, incu-
bation with T3 resulted in a significant increase of DUSP1
protein levels, which decayed at a lower rate in the pres-
ence of cycloheximide (half-life of 24.23  5.21 min). To
confirm that T3 was indeed decreasing the degradation
of the DUSP1 protein by the ubiquitin-proteasome sys-
tem, cells were treated in the presence or absence of the
inhibitor MG132, and DUSP1 levels were monitored by
Western blotting. Figure 5E shows that DUSP1 protein
was, in fact, stabilized in the presence of the proteasome
inhibitor, both in control and T3-treated cells.
All these data confirm that T3 induces DUSP1 pro-
tein at a posttranslational level by a mechanism de-
pendent on ERK.
The Effects of Thyroid Hormone on the NF-B
Pathway and Apoptosis in GH4C1 Cells Are
Mediated by DUSP1
We next investigated the role of DUSP1 on both T3-
mediated inhibition of the NF-B pathway and apo-
ptosis in GH4C1 cells. To address this question, cells
were transiently transfected with either a control small
interfering RNA (siRNA) (siControl) or with two specific
siRNAs to knock down DUSP1 expression (siDUSP1).
Fig. 4. The Apoptosis Induced by Thyroid Hormone Is Specifically Mediated by ERK
A, GH4C1 cells were maintained in the presence or absence of T3 (5 nM) in 10% (control) or 0.1% (SD) charcoal-stripped-FBS
for 48 h. Total cell lysates were prepared and analyzed by Western blotting with antibodies against phospho-JNK, total JNK,
phospho-p38, total p38, phospho-ERK, or ERK2. The blots shown are from a representative experiment performed twice with
similar results. B, Cells were incubated for 48 h in the presence of 10% (control) or 0.1% (SD) charcoal-stripped-FBS, in the
presence or absence of T3 (5 nM) plus vehicle or the inhibitors SP600125 (5 M), SB203580 (5 M), or U0126 (10 M). Apoptosis
was determined in PI-stained cells and analyzed by flow cytometry. The values represent the mean  SD of three independent
experiments performed in duplicate. SB, SB203580; SP, SP600125; U0, U0126.
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When the levels of DUSP1 mRNA were monitored by
QRT-PCR, the DUSP1 siRNAs attenuated DUSP1
mRNA expression, reducing the transcript levels by
about 80% of that in control cells (Fig. 6A). Hence, the
siRNAs were capable of reducing DUSP1 expression.
To assess the role of DUSP1 on the T3-mediated
inhibition of NF-B transcription, cells were cotrans-
fected with the 3NF-B-Luc reporter together with
the control siRNA or the DUSP1 siRNAs. As expected,
when the cells were incubated for 48 h with T3 in low
serum, T3 reduced NF-B-mediated transcription to
about 40% of control cells (Fig. 6B, left panel). By
contrast, the inhibition by T3 was almost completely
abolished in DUSP1 siRNA-transfected cells (Fig. 6B,
left panel). Because we have shown that T3 induces
DUSP1 in an ERK-dependent manner (Fig. 5B), we
analyzed the effect of the MEK inhibitor U0126 on the
T3-mediated inhibition of NF-B-dependent transcrip-
tion. As expected, incubation of the cells with U0126
partially impaired the inhibition of NF-B-dependent
transcription caused by T3, reaching a T3-mediated
inhibition of 46% in cells treated with U0126 vs. a 70%
inhibition in cells incubated in the absence of the in-
hibitor (Fig. 6B, right panel). To examine whether the
effect of DUSP1 on NF-B-mediated transcription in-
volved modification of p65/NF-B nuclear transloca-
tion, cells were transfected with either the control or
the DUSP1 siRNAs and incubated for 48 h with or
without T3 in low serum. T3 almost completely dimin-
ished p65/NF-B translocation to the nucleus in con-
trol cells, whereas it did not affect the level of p65/
NF-B in the nucleus of cells transfected with the
DUSP1 siRNAs (Fig. 6C). These data indicate that
DUSP1 mediates the inhibition of the NF-B pathway
caused by T3 in GH4C1 cells.
Because we have shown that the MEK/ERK path-
way is involved in T3-induced apoptosis (Fig. 4B) and
DUSP1 induction (Fig. 5B) in GH4C1 cells, we ex-
plored the possible involvement of DUSP1 in T3-in-
duced apoptosis. GH4C1 cells were transfected with
either the control siRNA or the specific DUSP1 siRNAs
and then incubated with T3 for 48 h. Subsequently,
apoptosis was measured in these cells by flow cytom-
etry (Fig. 6D). Although the basal level of apoptosis in
these cells was high, probably due to the transfection
procedure itself, nevertheless T3 enhanced the apo-
ptosis caused by serum depletion in cells transfected
with the control siRNA. Interestingly, cells transfected
with the DUSP1 siRNA showed less apoptosis than
control cells when incubated in low serum, and T3 did
not augment apoptosis under these conditions (Fig.
6D). To confirm the involvement of DUSP1 in T3-me-
Fig. 5. Thyroid Hormone Induces DUSP1 at a Posttranslational Level
A, GH4C1 cells were incubated for 48 h with T3 (5 nM) in the presence of 10% (control) or 0.1% (SD) charcoal-stripped-FBS,
and the total cell extracts were analyzed by Western blotting using antibodies against DUSP1. Equal protein loading was
evaluated by assessing -actin. B, Cells were incubated for 48 h in 0.1% charcoal-stripped-FBS with T3 (5 nM) plus vehicle or
U0126 (10 M), and DUSP1 expression was analyzed by Western blotting. Equal protein loading was evaluated by assessing
-actin. C, Cells were incubated for the indicated times in 0.1% charcoal-stripped-FBS with T3 (5 nM). Total RNA was prepared
and subjected to Northern blotting using a specific probe against DUSP1. D, Cells were incubated for 48 h in 0.1% charcoal-
stripped-FBS with T3 (5 nM), cycloheximide (10 g/ml) was then added, and DUSP1 protein levels were detected by Western
blotting. The blot and the graph shown are from one representative experiment performed three times with similar results. E, Cells
were incubated in 0.1% charcoal-stripped-FBS with MG132 (10 M) for 4 h before the addition of T3 (5 nM). After 48 h incubation,
total cell extracts were analyzed by Western blotting using antibodies against DUSP1. U0, U0126.
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diated apoptosis, we next incubated the cells for 48 h
with T3 in the presence or absence of the DUSP1
inhibitor, RO-31-8220. Incubation of the cells with the
inhibitor completely prevented the induction of apo-
ptosis by T3 (Fig. 6E).
Together, these data demonstrated that both T3-
mediated inhibition of NF-B and T3-induced apopto-
sis in GH4C1 cells are mediated by ERK-induced
DUSP1 expression.
DISCUSSION
The data presented here demonstrate that T3 induces
apoptosis in GH4C1 pituitary cells through a mecha-
nism dependent on ERK, DUSP1, and NF-B. Indeed,
we show that T3 induces DUSP1 via ERK, leading to a
down-regulation of NF-B activity and the induction of
apoptosis.
Programmed cell death and apoptosis have a fun-
damental role in tissue homeostasis. Growth factors
and serum provide both mitogenic and antiapoptotic
signals to cells and therefore play an important role in
maintaining the homeostatic balance between cell
proliferation and cell death. The mitogenic effects of
these factors have been well described, and a growing
body of literature has demonstrated that their with-
drawal can induce programmed cell death in several
cell systems. In particular, it has been shown that
primary pituitary cells require trophic support for sur-
vival in culture, and serum deprivation is an estab-
lished model for analyzing apoptotic pathways in
these cells (2). Our data support the idea that low
serum conditions are necessary for T3 to induce apo-
ptosis in diverse pituitary cell lines, including GH4C1,
GH1, and GH3B6 cells. The proposal that T3 modu-
lates apoptosis in pituitary cells is in agreement with
previous findings that T3 augments the mitochondrial
proapoptotic molecules Bax and Bak, diminishing the
antiapoptotic protein Bcl-2 in the closely related pitu-
itary cell line, GH3 (14). However, our results seem to
contrast with those indicating that T3 mediates the
Fig. 6. The Effects of Thyroid Hormone on the NF-B Pathway and Apoptosis in GH4C1 Cells Are Mediated by DUSP1
A, Cells were transiently transfected with either a control siRNA (siControl) or with two different siRNAs to knock down DUSP1
(siDUSP1), and they were treated for 48 h with T3 (5 nM) in 0.1% charcoal-stripped-FBS. Total RNA was extracted, and the levels
of DUSP1 mRNA were monitored by QRT-PCR. DUSP1 mRNA levels were normalized by GAPDH, and the results are expressed
as the change in mRNA expression. The values represent the mean  SD of a representative experiment performed in duplicate
and repeated twice with similar results. B (left), Cells were cotransfected with the 3NF-B-Luc reporter and the control siRNA
or the DUSP1 siRNAs and then incubated for 48 h with T3 in the presence of 10% (control) or 0.1% (SD) charcoal-stripped-FBS.
Cell extracts were prepared and assayed for luciferase and Renilla activities. The luciferase levels were normalized with those of
Renilla and expressed as the induction over the controls. The data shown represent the mean  SD of two independent
experiments performed in duplicate. B (right), Cells were transiently transfected with a NF-B-driven luciferase reporter plasmid
(3NF-B-TK-Luc) and pRL-TK-Renilla and then treated for 48 h in 0.1% charcoal-stripped-FBS with T3 (5 nM) plus vehicle or
U0126 (10 M). Cell extracts and luciferase activity were measured as above. C, Cells were transfected with either the control
siRNA or the DUSP1 siRNAs and incubated for 48 h with or without T3 in 0.1% charcoal-stripped-FBS. The nuclear extracts were
analyzed by Western blotting using antibodies against p65. Equal protein loading was evaluated by assessing -actin. The blots
shown are from one representative experiment performed twice with similar results. D, Cells were transfected with either the
control siRNA or the DUSP1 siRNAs and incubated for 48 h in the presence or absence of T3 in 10% (control) or 0.1% (SD)
charcoal-stripped-FBS. Apoptosis was determined in PI-stained cells and analyzed by flow cytometry. Values represent the mean 
SD of two independent experiments performed in duplicate. E, Cells were incubated for 48 h in 0.1% charcoal-stripped-FBS with T3
(5 nM) plus vehicle or RO-31-8220 (5 M). Apoptosis was determined in PI-stained cells and analyzed by flow cytometry. The values
represent the mean  SD of two independent experiments performed in duplicate. RO, RO-31-8220; U0, U0126.
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proliferation of GC and GH4C1 cells (11, 12). It is
probable that the different cell context explains this
apparent contradiction and indeed, in these earlier
studies the cells were maintained in medium supple-
mented with 10% charcoal-stripped fetal calf serum,
conditions in which T3 does not induce apoptosis of
GH4C1 cells. In contrast, the induction of apoptosis by
T3 in cells maintained in low serum is in accordance
with the suggestion that T3 stimulates the division of
GH4C1 cells through the secretion of a growth factor,
which might promote proliferation in conjunction with
other activities present in serum (11). Together, these
data show that T3 can exert opposing effects depend-
ing on the cell context, promoting either cell prolifer-
ation or cell death.
Our results also show that T3 causes sustained ac-
tivation of ERK and that T3-mediated apoptosis of
GH4C1 cells in low serum is dependent on this kinase.
T3 can activate ERK to a lesser extent in cells incu-
bated in high serum conditions, although this is not
sufficient to induce apoptosis. These findings suggest
that a threshold of ERK activation is necessary to
promote apoptosis in our cells. The role of T3 in ERK
signaling has been previously described in TtT-97
mouse thyrotrope tumor cells, in which T3 activates
the ERK pathway and induces the arrest of S-phase
progression (26, 27). In general, ERK activation is as-
sociated with cell survival and proliferation (47), al-
though activation of ERK by different stimuli has re-
cently been found to contribute to cell death in diverse
primary cultured cells (24, 25). More interestingly, sus-
tained activation of ERK was shown to be crucial in the
apoptosis caused by different stimuli in GH3 (28) and
in GH4C1 cells (29). Our results support this idea be-
cause T3 can act as a proapoptotic molecule in
GH4C1 cells through a mechanism that involves ERK
activation.
To our knowledge, this is the first time T3 has been
shown to induce DUSP1 expression, although this is in
agreement with a growing number of reports where
other nuclear receptors regulate DUSP1. For instance,
it was previously shown that glucocorticoid receptors
induce DUSP1 expression in different cell types (39,
48–50), whereas other nuclear receptors have also
been shown to regulate DUSP1 expression, albeit to a
lesser extent. For example, retinoid acid up-regulates
DUSP1 expression in different cells (51–53), and es-
trogen receptors increase basal levels of DUSP1 in
mesangial cells (54). It is also significant that T3-me-
diated induction of DUSP1 is dependent on the MEK/
ERK pathway. Although different mechanisms have
been shown to be involved in DUSP1 expression, the
main regulator seems to be ERK, which induces,
phosphorylates, and stabilizes DUSP1 by impeding its
proteolytic degradation (46, 55). Our data show that T3
induces DUSP1 protein by a posttranslational mech-
anism, increasing the half-life of the protein and de-
creasing its degradation via the ubiquitin-proteasome
pathway. Although the DUSP1 phosphorylation level
remains to be examined, our results suggest that T3
might induce DUSP1 phosphorylation via ERK in
GH4C1 cells.
DUSP1 seems to be crucial for T3-mediated apo-
ptosis of GH4C1 cells because silencing DUSP1 ex-
pression abrogates the induction of apoptosis caused
by T3. Interestingly, this effect is comparable to that
produced by blocking MEK and the downstream ERK
pathway, illustrating the link between the effects of T3,
ERK signaling, and DUSP1 induction. In contrast, spe-
cific inhibition of JNK or MAPK p38 signaling has no
effect on T3-mediated apoptosis, demonstrating that
these kinases do not participate in this process. How-
ever, JNK and MAPK p38 are likely to fulfill other
important functions in pituitary cells, which may be
regulated by DUSP1 and therefore, affected by T3. In
this regard, we observed that T3 can down-regulate
the increase of MAPK p38 phosphorylation in re-
sponse to TNF in GH4C1 cells (data not shown), and
this could influence processes other than apoptosis.
This study also provides evidence that T3 can in-
duce apoptosis by down-regulating NF-B activity.
The function of NF-B in anterior pituitary cells has, to
date, received little attention; however, our results
show that NF-B can be regulated by T3. Previous
studies have shown that inhibition and interruption of
the NF-B pathway can modulate the expression of
Bcl-2 and IAP family members in different cell types.
We found that T3 exerts an inhibition of Bcl-xL mRNA
expression, a member of the Bcl-2 family recently
shown to play an important role in the programmed
cell death of pituitary GH4C1 cells triggered by epi-
dermal growth factor (29). Moreover, T3 inhibits r-IAP1
and r-IAP3 mRNA expression, two members of the IAP
family. These findings strongly suggest that the T3-
induced apoptosis in GH4C1 cells is achieved, in part,
by the regulation of NF-B-responsive genes known to
be important modulators of apoptotic processes. The
specific role of each of these proapoptotic genes, as
well as other still unidentified genes, in T3-mediated
apoptosis in GH4C1 cells remains to be established.
Although NF-B can regulate T3-mediated tran-
scription (56, 57), for the first time our data show a
negative regulation of the NF-B signaling pathway by
T3. Functional cross talk between nuclear receptors
and NF-B has been reported for various classes of
receptors. Activated NF-B impairs the function of
receptors for glucocorticoids, progesterone, andro-
gens, and cholesterol, as shown in several in vitro
studies (58–61). In accordance with our data, these
receptors inhibit the action of NF-B in the presence of
their cognate ligands. For example, glucocorticoids
exert their antiinflammatory effects, at least partially,
through the inhibition of NF-B. Moreover, glucocor-
ticoids can inhibit NF-B in a variety of ways in differ-
ent cell contexts, including inhibition of DNA binding,
IB kinase (IKK) activity, and p65/NF-B transactiva-
tion (58). Similarly, estrogens can act through the
estrogen receptor to inhibit NF-B by a variety of
mechanisms (62, 63). We show here that T3 inhibits
NF-B-dependent transcription in GH4C1 cells by af-
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fecting the phosphorylation of IB and translocation
of active NF-B complexes from the cytosol to the
nucleus, by binding to B sequences in DNA, and by
p65/NF-B transactivation through a mechanism in-
volving the ERK activation and DUSP1 induction.
We also demonstrate that T3-mediated inhibition of
p65/NF-B translocation to the nucleus depends on
DUSP1 expression, because impairing DUSP1 gene
expression abrogates the effect of T3. Regulation of
the NF-B pathway by DUSP1 is not surprising, con-
sidering that this protein has been identified as one of
the components of the IKK signalsome. Indeed,
DUSP1 coassociates with IKK, and it was speculated
that DUSP1 (or the DUSP1-reactive protein identified
in the IKK signalsome) might be the phosphatase re-
sponsible for down-regulating IKK/ activity (64).
This down-regulation may occur by direct dephos-
phorylation of IKK at the crucial 176/177 serine residue
or, perhaps, by modulating the activity of an upstream
kinase. This hypothesis could explain our data show-
ing that T3 induced inhibition of NF-B through a
mechanism dependent on DUSP1 expression, al-
though this remains to be demonstrated.
Although nuclear translocation of NF-B has been
regarded as the principal method to activate NF-B-
dependent gene expression, alternate mechanisms of
NF-B activation are emerging, such as the phosphor-
ylation of the p65/NF-B subunit (18, 65). The phos-
phorylation of p65/NF-B in the cytoplasm or nucleus
is specific to both stimuli and cell type. So far, a great
number of p65/NF-B protein kinases have been iden-
tified, such as the IKK complex, protein kinase A,
glycogen synthase kinase 3, protein kinase C, CK2,
p38 MAPK, or AKT, and their role in NF-B activation
has been extensively described (18). In most cases,
this phosphorylation enhances the transactivation po-
tential of p65. Our data also show that T3 decreases
both the phosphorylation of nuclear p65/NF-B and its
transactivation potential, which correlates with the de-
crease in NF-B-dependent transcription observed.
These results are in agreement with earlier data show-
ing that p65/NF-B phosphorylation enhances p65/
NF-B transactivation potential. It has been shown
previously that p65/NF-B and T3 nuclear receptors
do not physically interact in yeast two-hybrid systems
(56), suggesting that the repressive effect of T3 on
p65/NF-B transactivation is not due to a direct inter-
action between these transcription factors. However,
we cannot exclude a possible interaction in the con-
text of native promoters. An alternative mechanism for
the transrepression of NF-B activity by T3 could in-
volve the sequestering of common cofactors shared
between NF-B and TR, such as cAMP response
element-binding protein-binding protein/p300 or his-
tone deacetylases (HDACs). p65/NF-B has been
shown to interact with HDAC1 and HDAC2, inhibiting
the transactivation function of NF-B in both basal
and stimulated situations (66). Because T3 attenu-
ates p65/NF-B-dependent transcription, we exam-
ined whether treatment with the HDAC inhibitor, tri-
chostatin A, had any effect on T3-NF-B-dependent
transcription. Trichostatin A did counteract the inhib-
itory action of T3 on NF-B-dependent transcription
(data not shown), and these data indicate that HDAC
activity is involved in the control of NF-B transcription
by T3 in GH4C1 cells, although the underlying mech-
anism requires further investigation.
In conclusion, our data show a novel proapoptotic
function of T3 in GH4C1 cells that is produced through
ERK activation, DUSP1 induction, and NF-B down-
regulation. These results could have important impli-
cations for the understanding of pituitary cell ho-
meostasis in different physiopathological situations,
including the apoptotic process that occurs naturally
in the pituitary gland during postnatal life.
MATERIALS AND METHODS
Materials and Plasmids
Tissue culture media and sera were obtained from Life Tech-
nologies, Inc. (Gaithersburg, MD). The antibodies used were:
antidual phosphorylated ERK, antiphosphorylated p38
MAPK, anti-pSer276-NF-B, and antiphospho-IB (Cell Sig-
naling Technology, Danvers, MA); antiphosphorylated JNK
(Promega Corp., Madison, WI); anti-ERK2, anti-p38 MAPK,
anti-JNK, anti-MAPK phosphatase 1, anti-NF-B/p65, anti-
IB, and anti-PARP (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA); anti--actin and antitubulin (Sigma Chemical Co.,
St. Louis, MO); antihistone H3 (Abcam, Inc., Cambridge, MA);
and peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology). The p38 MAPK inhibitor SB203580, the
JNK inhibitor SP600125, and the DUSP1 inhibitor RO-31-
8220 were all obtained from Calbiochem (La Jolla, CA). The
MEK inhibitor U0126 was purchased from Promega. T3 and
MG-132 were from Sigma. The 3NF-B-TK-Luc reporter
plasmid, which contains a three-tandem repeat of the NF-
B-binding motif of the H-2k gene upstream of the thymidine
kinase minimal promoter (67) was kindly provided by Dr. M.
Fresno (Centro de Biología Molecular Severo Ochoa, Con-
sejo Superior de Investigaciones Cientificas-UAM, Madrid,
Spain). The plasmid containing the Gal4-DNA-binding do-
main fused to the full-length human p65/NF-B coding se-
quence (pGal4-p65) (68) and the Gal4-p65 mutant construct
[pGal4-p65(S276C)] were obtained from the BCCM/LMBP
Plasmid Collection (Ghent, Belgium). The plasmid pGal4-Luc
and the probe for EMSAs (69) were kindly provided by Dr. R.
Perona (Instituto de Investigaciones Biome´dicas, Consejo
Superior de Investigaciones Cientificas-Universidad Au-
tónoma de Madrid, Madrid, Spain).
Cell Culture
GH4C1 cells were cultured in DMEM supplemented with
10% FBS. GH3B6 or GH1 cells were cultured in Hams F10
or RPMI medium supplemented with 10% horse serum (HS)
and 2.5% FBS, respectively. In the experiments, the cell
medium was replaced by fresh medium containing either
10% or 0.1% AG1x8 resin and charcoal-stripped FBS (for
GH4C1 cells) or HS (for GH1 and GH3B6 cells), and cells
were incubated for the indicated time periods in the presence
or absence of T3. Control cells were incubated with the
same volume of the vehicle used to dissolve the different
compounds.
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Cell Transfection
GH4C1 cells were transfected by electroporation, as de-
scribed previously (70). Briefly, 2–3  106 cells were mixed
with the reporter plasmids and exposed to a high-voltage
pulse (170–200 V, 960 F) in a Bio-Rad electroporator with a
capacitor extender (Bio-Rad Laboratories, Richmond, CA).
The cells from each electroporation were plated in different
dishes with hormone-depleted media and incubated with the
different treatments as necessary.
siRNA Oligos and Transfections
siRNA oligos for DUSP1 were obtained from Ambion, Inc.
(Austin, TX): siRNA (identification no. 55543), forward (5-
GGG UCA CUA CCA GUA CAA Gtt-3), reverse (5-CUU GUA
CUG GUA GUG ACC Ctc-3); siRNA (identification no.
55635), forward (5-GGC AGA CAU UAG CUC CUG Gtt-3),
reverse (5-CCA GGA GCU AAU GUC UGC Ctt-3). Trans-
fections were carried out by electroporation as described
above using the siPORT siRNA Electroporation Buffer (Am-
bion), and 2 M of each siRNA or the scrambled siRNA
(silencer negative control 1 siRNA, Ambion). Cells were
plated on 60-mm plates and left for 24 h in DMEM supple-
mented with 10% FBS. The media were replaced with DMEM
plus 0.1% or 10% resin and charcoal-stripped FBS, and the
cells were then incubated in the presence or absence of T3
for 48 h.
NF-B Reporter Assays
The NF-B reporter assay was performed as described pre-
viously (67) with minor modifications. Cells were transfected
as described above with 2 g of the 3NF-B-TK-Luc or
TK-Luc reporter plasmids and 0.6 g of the common internal
transfection standard Renilla in the pRL-TK plasmid, which
was used to normalize transfection efficiency. The cells were
harvested in 100 l reporter lysis buffer (Promega) 48 h after
transfection, and dual luciferase and Renilla reporter assays
were performed following the protocol provided by the man-
ufacturer. To measure the transactivating potential of p65/
NF-B, cells were transfected with the fusion construct
pGal4-p65, pGal4-p65(S276C), or pGal4 alone (2 g) and the
pGal4-Luc reporter plasmid (4 g). Luminescence was mea-
sured in 10 l of the cell extract, and the protein concentra-
tion was determined by the Bradford protein assay. Each
treatment was performed in duplicate cultures that normally
showed less than a 5% variation in luciferase activity. Each
experiment was repeated at least three times with similar
differences in regulated expression, and all data are ex-
pressed as the mean  SD.
Real-Time Quantitative RT-PCR
Real-time quantitative RT-PCR was performed on the Real-
Time PCR System Mx3005P (Stratagene), monitoring the
increase of fluorescence due to the binding of SYBR Green to
double-stranded DNA. Dissociation analysis was performed
at the end of each PCR to ensure that only the specific
product was amplified. The first-strand cDNA template was
synthesized from 5 g of total RNA using oligodeoxythymi-
dine in 20 l of water, following the instructions of the Su-
perScript First Strand Synthesis System (Invitrogen Life
Technologies, Carlsbad, CA). For a 25-l PCR, 2 l of cDNA
template was mixed with forward and reverse primers (each
primer at final concentration150 nM) and 2 Brilliant SYBR
Green QPCR Master Mix (Stratagene). The gene-specific
primers and the conditions of each reaction were as follows:
r-IAP1: forward (5-GAT TTG CAC ACT CGC TAC CT-3),
reverse (5-CCA GTT GCT CAG TTT CCC AC-3), 95 C, 30
sec, 54 C, 1 min, 72 C, 1 min, 40 cycles; r-IAP3: forward
(5-CGG CAG TAG ATA GAT GGC AG-3), reverse (5-CTC
TCT GGG GCT TAA ATG GG-3), 95 C, 30 sec, 54 C, 1 min,
72 C, 1 min, 40 cycles; Bcl-xL: forward (5-TAT TGG TGAGTC
GGA TTG CA-3), reverse (5-GAG ATC CAC AAA AGT GTC
CCA-3), 95 C, 30 sec, 52 C, 1 min, 72 C, 1 min, 40 cycles;
DUSP1: forward (5-GAT CAA CGT CTC GGC CAA TT-3),
reverse (5-GCA CAA ACA CCC TTC CTC CA-3), 95 C, 30
sec, 50 C, 30 sec, 72 C, 1 min, 40 cycles; glyceraldehyde-
3-phosphate dehydrogenase (GAPDH): forward (5-ACA
CTG CAT GCC ATC ACT GCC-3), reverse (5-GCC TGC TTC
ACC ACC TTC TTG-3), 95 C, 30 sec, 55 C, 1 min, 72 C, 1
min, 40 cycles. To quantify changes in gene expression, the
Ct method was used to calculate the relative changes
normalized against the GAPDH gene.
Northern Blot Analysis
Northern blot was performed as previously described (48).
Briefly, total RNA was isolated using the TRI Reagent (Sigma),
and 10 g RNA samples were electrophoresed on denaturing
formaldehyde-agarose gels. RNA was transferred to Hybond
N membrane, and DUSP1 mRNA was detected with a spe-
cific cDNA probe labeled with the Ready-to-go kit (Amer-
sham Pharmacia Biotech, Piscataway, NJ). Signals were vi-
sualized by exposure to Kodak Biomax film (Eastman Kodak,
Rochester, NY).
Cell Extracts
For total cell extracts, cells were harvested after treatment in
100 l lysis buffer [20 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10%
glycerol, 100 mM KCl, 1% Triton X-100, 0.3% 2-mercapto-
ethanol, 5 mM NaF, 0.2 mM Na3VO4, 5 mM MgCl2] supple-
mented with protease inhibitors, and the lysates were clari-
fied by centrifugation at 13,000 g for 10 min at 4 C. Nuclear
extracts were prepared as described (71). Briefly, cells were
washed and recovered in a hypotonic buffer containing: 10
mM HEPES (pH 7.4), 0.1 mM EDTA, 10 mM KCl, 1 mM dithio-
threitol (DTT), 1% Triton X-100, and 0.2% sucrose supple-
mented with protease inhibitors. After a 10-min incubation at
4 C, the cell nuclei were collected by centrifugation at
30,000  g at 4 C for 10 min. The pellet containing the nuclei
was resuspended in elution buffer (20 mM HEPES, pH 8; 25%
glycerol; 0.42 M NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM DTT)
supplemented with protease inhibitors, and after a 45 min
extraction at 4 C the nuclear membranes were sedimented at
30,000 g for 30 min at 4 C. The nuclear proteins were finally
collected in the supernatant and stored in aliquots at 70 C.
Western Blot Analysis
Cells were incubated as described in the figure legends and
then harvested in lysis buffer as described above. The protein
content of the cell or nuclear extracts was normalized, the
samples were separated by SDS-PAGE, and then transferred
to nitrocellulose membranes. The membranes were probed
with the primary antibodies indicated and that in turn were
detected with a peroxidase-coupled secondary antibody. An-
tibody binding was visualized using the enhanced chemilu-
minescence system (Amersham).
EMSA
DNA binding was assessed by EMSA according to standard
protocols. As such, 2 g of the nuclear extracts was incu-
bated in 40 mM HEPES (pH 7), 12.5 mM MgCl2, 140 mM NaCl,
1 mM EDTA, 5 mM DTT, 0.01% Nonidet P-40, 4% Ficoll, and
0.2 g of polydeoxyinosinic deoxycytidylic acid for 15 min at
4 C. Subsequently 10,000 cpm of a 32P-labeled probe con-
taining the NF-B binding site (69) was added to the samples
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and left for 20 min at room temperature to permit DNA-
protein binding. The protein-DNA complexes formed were
separated in 5% nondenaturing polyacrylamide gels in 0.5%
Tris-borate-EDTA buffer, and the gels were then dried and
the bands visualized by exposure to Kodak Biomax film.
Flow Cytometry Analysis of Apoptosis
Apoptosis was identified and quantified by flow cytometry
after PI staining. Adherent and floating cells were collected
after treatment, washed with ice-cold PBS, and fixed with
70% ice-cold ethanol (30 min, 4 C). The fixed cells were
washed twice with PBS and treated with ribonuclease (1
mg/ml for 30 min at 37 C). Cellular DNA was stained PI (5
g/ml in PBS), and the cells were analyzed on a FACScan
flow cytometer (Becton Dickinson and Co., Franklin Lakes,
NJ). The percentages of cells in different phases of the cell
cycle were calculated from the DNA histograms. Cells with
sub-G1 DNA content were considered apoptotic.
Apoptosis was also examined by the Annexin V/PI dual
staining assay. Cells were collected after treatment and were
mixed with 10 l of fluorescein isothiocyanate-conjugated
annexin V reagent (R&D Systems, Abingdon, UK) and 10 l of
3 mM PI. After incubation, samples were analyzed by flow
cytometry. The percentage of early apoptotic cells, late ap-
optotic cells, and dead cells is shown at the top of each
panel.
Statistical Analysis
All data are expressed as means  SD. In statistical analysis,
Student’s t test was performed using the SSC-Stat software
(version 2.18, University of Reading, Reading, UK). The sta-
tistical significance of difference between groups was ex-
pressed by asterisks (*, 0.01 P 0.05; **, 0.001 P 0.01;
***, P  0.001).
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